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Abstract. Psoriasin, which is also known as S100A7, is a member 
of the S100 protein family, a group of calcium‑responsive 
signalling proteins. Psoriasin expression remains high in 
patients with psoriasis, whereas it is downregulated in patients 
with invasive breast carcinoma. This observation suggests 
that this protein may be a notable marker of keratinocyte 
function and differentiation during wound healing. The aim 
of the present study was to determine the cellular impact of 
Psoriasin in keratinocytes, which are the primary cell type 
associated with wound healing. Psoriasin expression in wound 
tissues was examined using reverse transcription‑quantitative 
polymerase chain reaction and immunochemical staining. 
Knockdown of Psoriasin in HaCaT cells was performed using 
anti‑Psoriasin ribozyme transgenes and the effect on growth, 
adhesion and migration of keratinocytes was subsequently 
determined using in vitro cellular functional assays. Psoriasin 
expression is upregulated in wounds, particularly at the 
wound edges. The present study demonstrated that Psoriasin 
is expressed in keratinocytes and is a fundamental regulator 
of keratinocyte migration. Significant increases in the rate of 
keratinocyte adhesion, migration and growth were observed 
in Psoriasin‑deficient cells (P<0.01 vs. control). Application of 
small inhibitors identified the potential association of neural 
Wiskott‑Aldrich syndrome protein, focal adhesion primase 
and rho‑associated protein kinase signalling pathways with 
Psoriasin‑regulated cell adhesion and motility. In conclu‑
sion, Psoriasin serves an important role in the wound healing 
process, suggesting that it may be utilized as a potential wound 
healing biomarker.
Introduction
Chronic wounds, such as diabetic foot ulcers and venous and 
arterial leg ulcers, pose a major health risk to patients and place 
marked financial, resource and time burdens on the healthcare 
system. In industrialised countries, ~1% of the population 
experiences a non‑healing wound, which accounts for a signifi‑
cant part of the healthcare budget (1). In 1998, it was estimated 
that chronic wounds would cost the National Health Service 
in the United Kingdom (UK) a total of £1 billion per year (2). 
Between 2005 and 2006, there were 200,000 individuals in 
the UK with chronic wounds, accounting for £2.3‑3.1 billion 
per year, or 3% of the total estimated out‑turn expenditure on 
health for the same period (£89.4 billion) (2,3). The cost may 
become much higher as the number of people suffering from 
chronic wounds in the UK increases; for example, in 2011, this 
figure was estimated to be >600,000 (4).
Advances in molecular biology have helped to elucidate 
the complexities of wound biology. Menke et al (5) describe 
the nature of wound healing biology as ʻcomplex, multiscale, 
multitemporal and hierarchicalʼ . Past failures in wound diag‑
nosis and monotherapies may be due to the under appreciation 
of this complexity. The signalling mechanisms of growth 
factors have been well studied (6,7), and reduced levels in 
the wound environment may be partially responsible for the 
failure of certain wounds to heal. It has been demonstrated 
that chronic ulcers exhibit reduced levels of platelet derived 
growth factor, epidermal growth factor, basic fibroblast growth 
factor, and transforming growth factor β compared with acute 
wounds, typically as a result of trapping or degradation (6,7).
The imbalance between proteinases and their inhibi‑
tors with excessive proteinase activity in chronic wounds, 
which is potentially due to the overexpression of matrix 
metalloproteinase, results in abnormal degradation of the 
extracellular matrix (8‑10). Dermal fibroblasts exhibit an 
age‑related decrease in proliferation potential, or cell senes‑
cence, and it has previously been demonstrated that fibroblasts 
isolated from chronic wounds have a decreased or non‑existent 
replicative ability (11). In addition, cell senescence, in the 
form of epidermal arrest, has been demonstrated in kerati‑
nocytes (12). Further studies have shown that gene arrays of 
wound edges are able to guide specific cell subpopulations, 
which aid in targeting therapy and debridement (13,14). 
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Charles et al (15) compared the gene expression patterns of 
five non‑healing venous leg ulcers with five healing venous leg 
ulcers, and 15 genes were identified that were differentially 
expressed in the keratinocytes at the non‑healing wound edge. 
Among these was the S100 calcium‑binding protein A7 gene 
(Psoriasin), which expresses protein products that have been 
proposed to be associated with keratinocyte differentiation.
Psoriasin, which is also known as S100A7, belongs to the 
S100 protein family of calcium‑responsive signalling proteins. 
It was originally discovered in unfractionated non‑cultured 
keratinocytes as a novel protein with a low molecular weight 
(11.4 kDa) (16,17). It was found to be overexpressed in psoriatic 
keratinocytes and expressed at low levels in normal prolifer‑
ating keratinocytes and foetal skin (16). Although Psoriasin 
was initially studied as a secreted protein in psoriatic skin (17), 
it was later detected in the cytoplasm and nucleus of kerati‑
nocytes and breast epithelial cells (18), suggesting that this 
protein has multiple functions. Psoriasin is homologous with 
the S100 genes as it encodes small cytoplasmic and secreted 
proteins that share EF‑hand‑helix‑loop‑helix domains, which 
are necessary for calcium binding (19). A total of 13 of the 
S100 proteins, including Psoriasin, are encoded within the 
epidermal differentiation complex of human chromosome 
1q21.2‑q22 (18,20,21). Many of these genes products, including 
Psoriasin, serve important roles in exerting the effects of 
calcium on cell growth and differentiation (22).
Although Psoriasin protein overexpression was initially 
discovered in patients with psoriasis (16), it has subsequently 
been discovered to be associated with other inflammatory 
skin conditions (23). Secreted Psoriasin has been demon‑
strated to have a chemotactic influence on inflammatory cells, 
suggesting a link with inflammatory skin diseases (24). The 
levels of Psoriasin in pre‑cancerous lesions of the breast and 
skin, as demonstrated in multiple studies (25‑28), indicate that 
Psoriasin expression is low in normal epithelium and increased 
in pre‑invasive carcinoma, specifically act in keratosis and 
breast carcinoma in situ, and that high Psoriasin levels are 
associated with unfavourable histological features and a worse 
clinical outcome in patients with breast cancer (29‑33). This 
suggests that Psoriasin may serve an important role in cancer 
progression.
Expression of Psoriasin in normal keratinocytes is 
known to be upregulated in response to calcium and retinoic 
acid stimuli, and in abnormal pathways of differentiation 
in culture (18,25,34). Among normal tissues, Psoriasin has 
restricted expression in the epithelial component of tissues, such 
as skin, breast and bladder (23,25,29,35). Furthermore, expres‑
sion is elevated in the differentiating layers compared with the 
basal cells, where Psoriasin is absent, thereby indicating that 
it may have a specific association with differentiation (25,36). 
Expression of Psoriasin in the context of wound healing was 
initially observed based on the regenerative similarities among 
wounds and psoriatic keratinocyte (37,38). The effects of 
Psoriasin in chronic venous ulcers were previously studied by 
Dressel et al (39) via immunohistochemical (IHC) staining, 
demonstrating a significant induction of Psoriasin among 
seven chronic venous wound margin biopsies compared with 
normal skin biopsies.
Psoriasin is important in many basic cellular functions 
and keratinocytes are associated with the re‑epithelisation 
of wound edges. Psoriasin expression in the epidermis and 
its association with the regulation of survival, adhesion and 
motility of various types of cells, suggests that it may have a 
function in aiding wound healing. The aim of the present study 
was to investigate the specific role of Psoriasin in keratinocyte 
cellular functions and its implication in chronic wounds.
Materials and methods
Materials and cell line. A universal IHC kit (Elite ABC Kit) 
was purchased from Vector Laboratories, Ltd. (Peterborough, 
UK). Total RNA isolation reagent (TRIzol) was purchased 
from Sigma‑Aldrich (Merck Millipore, Darmstadt, Germany), 
and reverse transcription kits (iScript) were obtained from 
Bio‑Rad Laboratories, Inc. (Hercules, CA, USA). Small inhibi‑
tors for neural Wiskott‑Aldrich syndrome protein (N‑WASP), 
focal adhesion kinase (FAK) and rho‑associated protein kinase 
(ROCK) were purchased from Merck Millipore. The HaCaT 
human keratinocyte cell line was purchased from The German 
Cancer Research Center (Heidelberg, Germany). Cells were 
maintained in Dubecco's modified Eagle medium (DMEM), 
which was supplemented with penicillin, streptomycin and 
10% fetal calf serum (PAA Laboratories, Ltd.; GE Healthcare 
Life Sciences, Chalfont, UK). Cells were incubated at 37˚C 
and 95% humidity in an atmosphere containing 5% CO2. 
Primer sequences are provided in Table I.
Chronic wound tissues and skin biopsies. Skin biopsies were 
obtained from patients attending the University Hospital 
of Wales (Cardiff, UK) wound healing clinic as described 
previously (40,41). Ethical approval was granted by the Local 
Research Ethics Committee and written informed consent 
was obtained from each patient. Biopsies were taken from 
14 patients with chronic leg ulcers and used during the present 
study. All wounds were present for ≥6 months, displaying no 
evidence of healing occurring six weeks prior to biopsy and had 
a minimum area of 4 cm2 prior to biopsy with no clinical indi‑
cations of infection. Venous disease was diagnosed by duplex 
ultrasonography using a Viamo system (Toshiba Medical 
Systems, Ltd., Crawley, UK). Following the administration 
of local anaesthetic (1% lidocaine; Hameln Pharmaceuticals, 
Ltd., Gloucester, UK), 6 mm punch biopsies, incorporating 
epidermis and dermis at the wound edge with adjacent granu‑
lation tissue, were harvested from the wound margin under 
aseptic conditions. Single wedge biopsies were obtained from 
10 patients with acute surgical wounds following excision 
of pilonidal disease. These wounds were determined to be 
clinically non‑infected. Biopsies were harvested from the edge 
of the healing wound within six weeks of excision surgery. 
Normal, unwounded skin was also obtained and examined as 
a control to provide a comparison with wound tissue. Under 
local anaesthetic (1% lidocaine), 3 mm punch biopsies were 
taken from the inner aspect of the upper arm of 10 healthy 
volunteers working within the Wound Healing Research Unit 
at the University Hospital of Wales.
IHC staining. Frozen sections from wound tissues were fixed 
in an acetone/methanol solution and rehydrated in wash 
buffer (Mena Path Autowash buffer; A. Menarini Diagnostics, 
Ltd., Winnersh, UK) and placed in a wash buffer solution 
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containing 10% horse serum (Vector Laboratories, Ltd.) to 
block non‑specific antigen binding. An avidin/biotin complex 
(ABC) IHC kit (PK‑6200, Vector Laboratories, Ltd.) was 
used. An anti‑Psoriasin polyclonal antibody, was diluted in 
a buffer that contained 1% horse serum and 0.1% Tween 20 
(Sigma‑Aldrich; Merck Millipore) at 1:40 dilution. Following 
1 h of incubation at room temperature with the primary anti‑
bodies, the slides were washed four times in wash buffer and 
incubated at room temperature with a universal biotinylated 
secondary antibody provided in the IHC kit (1:500; Vector 
Laboratories, Ltd.) for 30 min. Avidin and biotin were added 
through the addition of the ABC complex following washing. 
A 3,3'‑diaminobenzidinecolour developing system was used to 
indirectly detect protein staining. A series of graded alcohols 
were used to dehydrate sections, which were subsequently 
cleared in xylene, mounted and examined using a light micro‑
scope equipped with a digital camera (Olympus Corporation, 
Tokyo, Japan). Semi‑quantification was performed using 
ImageJ software (version 1.5; National Institutes of Health, 
Bethesda, MD, USA), with normalisation of data to the back‑
ground.
Psoriasin knockdown in HaCaT cells. Anti‑Psoriasin hammer‑
head ribozymes were designed based on the secondary 
structure of Psoriasin mRNA. The ribozymes were synthe‑
sised using a touchdown PCR procedure and subsequently 
cloned into a mammalian expression vector (pEF6/His TOPO 
vector; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA). The constructed anti‑Psoriasin transgenes and 
empty vectors were transfected into HaCaT cells according 
to a previously reported procedure (42). Following a period 
of blasticidin selection (5 µg/ml; Sigma‑Aldrich; Merck 
Millipore), the cells were maintained in DMEM containing 
0.5 µg/ml blasticidin. The selected transfectants were verified 
for the knockdown of Psoriasin (HaCaTPSOkd). HaCaTPSOkd, 
together with the control cells transfected with empty vectors 
(HaCaTpEF) and wild type cells (HaCaTWT), were used in the 
following experiments. Three independent transfections were 
performed to verify the knockdown of Psoriasin using the 
anti‑Psoriasin ribozymes.
RNA extraction, reverse transcription (RT), conventional 
polymerase chain reaction (PCR) and quantitative (q)PCR). 
RNA isolation from cells or tissues was performed using an 
ABgene Total RNA Isolation Reagent (TRIR) Kit (ABgene; 
Thermo Fisher Scientific, Inc.) in accordance with the manu‑
facturer's protocol. Briefly, cells were cultured in 25 cm2 flasks 
until 85‑90% confluent. The growth medium was subsequently 
removed and 1 ml of TRIR reagent was added to the monolayer 
to lyse the cells. Following RNA isolation, RNA was quanti‑
fied using a UV1101 photometer (WPA Biochrom; Biochrom, 
Ltd., Cambridge, UK) at 260 nm. cDNA was synthesised using 
an iScript cDNA synthesis kit (Bio‑Rad Laboratories) for a 
standardised 0.5 µg RNA in a 20 µl‑reaction. Conventional 
PCR was subsequently used to verify Psoriasin expression 
in transfected cells using REDTaq ReadyMix PCR reaction 
mixture comprising 20 mM Tris‑HCl (pH 8.3) with 100 mM 
KCl, 3 mM MgCl2, 0.002% gelatin, 0.4 mM dNTP mix (dATP, 
dCTP, dGTP, TTP), stabilizers, and 0.06 U/ml Taq DNA 
Polymerase (R2523; Sigma‑Aldrich; Merck Millipore) and a 
T‑Cy thermocycler (Creacon Technologies, B.V., Emmen, the 
Netherlands). Conditions for conventional PCR to amplify 
transcripts of Psoriasin were: 36 cycles at 94˚C for 30 sec, 
55˚C for 20 sec, 72˚C for 30 sec and a final extension phase of 
7 min at 72˚C. GAPDH was used as a housekeeping gene. PCR 
products were separated on a 1.5% agarose gel and stained 
with ethidium bromide prior to examination under UV light.
qPCR was used to determine Psoriasin transcripts in wound 
tissues following a previously reported method (43). An iCycler 
IQ system (Bio‑Rad Laboratories, Inc.) was used to determine 
Psorisain transcript levels. Each reaction contained 5 µl of the 
2x concentrated HotstarTaq‑master mix (ABgene; Thermo 
Fisher Scientific, Inc.), 1 µl of forward primer (10 pmol/µl), 
1 µl reverse primer (1 pmol/µl), 1 µl of a FAM‑tagged universal 
probe (10 pmol/µl; Intergen Co., Purchase, NY, USA), and 
cDNA samples. Conditions for qPCR were as follows: An 
initial 10 min 95˚C denature followed by 80 cycles of 95˚C for 
15 sec, 55˚C for 35 sec and 72˚C for 20 sec. Psoriasin transcript 
levels were normalised against corresponding GAPDH quan‑
tity. Primer sequences are provided in Table I.
SDS‑PAGE and western blot analysis. Cellular protein was 
extracted and lysed in Ca2+ and Mg2+ free HEPES buffer 
containing 0.5% SDS, 1% Triton X‑100, 2 mM CaCl2, 100 µg/ml 
phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml 
aprotinin and, 10 mM sodium orthovanadate (Sigma‑Aldrich; 
Table I. Primer sequences used for PCR.
Primer Forward Reverse
Psoriasin 5'‑GAGGTCCATAATAGGCATGA‑3' 5'‑AGCAAGGACAGAAACTCAGA‑3'
Psoriasin (qPCR) 5'‑TGTGACAAAAAGGGCACAAA‑3' 5'‑ACTGAACCTGACCGTACACCCAGCAA
  GGACAGAAACTC‑3'
GAPDH 5'‑ATGATATCGCCGCGCTCGTC‑3' 5'‑GCTCGGTCAGGATCTTCA‑3'
GAPDH (qPCR) 5'‑CTGAGTACGTCGTGGAGTC‑3' 5'‑ACTGAACCTGACCGTACAGAGATGATG
  ACCCTTTTG‑3'
Psoriasin ribozyme 5'‑CTGCAGTCACAGGCACTAAGG 5'‑ACTAGTGGCTGGTGTTTGAC
 AAGTTGGGCTGATGAGTCCGTGAGGA‑3' ATTTCGTCCTCACGGACT‑3' 
 
PCR, polymerase chain reaction; qPCR, quantitative PCR.
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Merck Millipore) on a rotor wheel for 1 h. Insoluble proteins 
were removed via centrifugation at 13,000 x g for 4˚C for 
15 min and quantified using a DC Protein Assay kit (Bio‑Rad 
Laboratories, Inc.). Samples were standardised and diluted in 
Laemmli 2x concentrate sample buffer (Sigma‑Aldrich; Merck 
Millipore) and boiled for 5 min. Following this, 20 µg total 
protein of each sample were separated by 12% SDS‑PAGE. 
The separated proteins were transferred to a nitrocellulose 
membrane via western blotting. Gels were removed from the 
electrophoretic tank and unclipped from the loading cassette, 
and the stacking gel was removed. The resulting gel was 
then carefully laid on top of a pre‑cut Hybond nitrocellulose 
membrane (GE Healthcare Life Sciences) in an SD20 Maxi 
System blotting unit (SemiDRY; Wolf Laboratories, Ltd., 
York, UK). Blots were probed with anti‑Psoriasin (1:250; 
ab13680; Abcam, Cambridge, UK) and anti‑GAPDH (1:500, 
SC‑47724, Insight Biotechnology, Ltd., Wembley, UK) mouse 
monoclonal antibodies following an overnight incubation with 
a blocking buffer which was 10% skimmed milk in tris‑buff‑
ered saline (TBS) at 4˚C. Peroxidase‑conjugated anti‑mouse 
antibody (1:1,000; A9044; Sigma‑Aldrich; Merck Millipore) 
was then added prior to visualising protein bands using the 
Supersignal West Dura system (Thermo Fisher Scientific, Inc.) 
and a gel imaging system (UVItec, Ltd., Cambridge, UK). The 
experiment was repeated three times at least for each subline.
In vitro growth assay. An in vitro growth assay was used to 
determine HaCaT cell growth. A total of 3,000 cells per well 
were seeded into 96 well plates. Triplicate plates were set up 
and incubated at 37˚C for three and five‑day periods prior to 
analyses. Following incubation, the plates were fixed in 4% 
formaldehyde (v/v), stained with 0.5% (w/v) crystal violet 
and treated with 10% acetic acid (v/v). Absorbance at 540 nm 
was determined using an ELx800 multi‑plate reader (BioTek 
Instruments Inc., Winnoski, VT, USA).
Adhesion and migration tests using electric cell‑substrate 
impedance sensing (ECIS) analysis. The ECIS 9600 system 
(Applied Biophysics Inc., Troy, NY, USA) was used to moni‑
torthe adhesion and migration of HaCaT cells, as previously 
described (44,45). Briefly, HaCaT cells were seeded onto ECIS 
96W1E arrays and adhesion of cells to the culture surface and 
electrodes was monitored via measuring electrical resistance. 
Once a confluent monolayer had been formed, the cells were 
damaged by applying electric current (1,400 µA, 60 kHz) for 
20 sec to create a break in the cell monolayer. The rate of 
change in impedance as cells migrated back onto the electrode 
was subsequently monitored and analysed.
Statistical analysis. The Minitab 14 statistical package 
(Minitab, Inc., State College, PA, USA) was used to identify 
statistically significant differences between the test groups 
using a two‑sample, two‑tailed, Student's t‑test. In vitro func‑
tional assays were repeated a minimum of three times. P<0.05 
was considered to indicate a statistically significant difference.
Results
Expression of Psoriasin in chronic wounds. Frozen sections of 
chronic wound tissue samples were stained to detect Psoriasin, 
as described previously, and tissue sections from the wound edge 
and distal edge were compared. IHC stained images from the 12 
wound samples are presented in Fig. 1A. Staining of Psoriasin 
revealed elevated protein levels throughout all epidermal layers 
in wounds, with the exception of the stratum basale. Furthermore, 
keratinocytes also demonstrated an increase in Psoriasin 
staining, in accordance with the secretory nature of the protein. 
Initial comparisons between samples revealed a less intense 
immunostaining of Psoriasin at the distal edges of the wounds 
compared with the wound edges. Semi‑quantification using 
ImageJ software revealed an increase ≤19.8% in the intensity 
of Psoriasin staining within the epidermal layers at the wound 
edge, in comparison with the epidermal staining at the distal 
wound (Fig. 1B). This indicates an upregulation of Psoriasin in 
the wound edges. Psoriasin mRNA transcript in tissues taken 
from the edge of acute and chronic wounds and normal skin 
was analysed (Fig. 1C). In acute wounds, there was a significant 
increase in Psoriasin mRNA expression (P=0.0021) compared 
with the chronic wound phenotype. A significant increase was 
also observed in Psoriasin expression between the acute wounds 
and the normal skin controls (P=0.037). Furthermore, Psoriasin 
expression was markedly lower in chronic wounds compared 
with the normal controls.
Knockdown of Psoriasin in HaCaT cells. The presence 
of Psoriasin in HaCaT keratinocytes was confirmed using 
RT‑qPCR. To examine the functional role of Psoriasin in kera‑
tinocytes, HaCaT cells were transfected with anti‑Psoriasin 
ribozyme transgenes. HaCaT Psoriasin knockdown in the 
HaCaTPSOkd cells was seen and its mRNA expression compared 
with the HaCaTWT and HaCaTpEF control cells using RT‑qPCR 
(Fig. 2A and B). Resulting protein levels of Psoriasin in 
HaCaTpEF and HaCaTPSOkd cells were evaluated using western 
blot analysis. As illustrated in Fig. 2C, Psoriasin protein was 
detected in the HaCaTpEF control cells with a corresponding 
reduction of Psoriasin protein levels in the HaCaTPSOkd cells. 
Semi‑quantifications showed a 41% reduction of Psoriasin 
protein expression in HaCaTPSOkd cells compared with the 
control cells (Fig. 2D).
Influence of Psoriasin knockdown on in vitro growth, adhe‑
sion and migration of HaCaT cells. Using the colorimetric 
growth assay method described previously, the effects of 
Psoriasin knockdown on HaCaT cells were evaluated and 
compared with the HaCaTpEF controls. Psoriasin knockdown 
significantly enhanced the growth rate of HaCaTPSOkd cells 
at three and five days compared with control HaCaTpEF cells 
(both P<0.01; Fig. 3A).
ECIS assay was performed to evaluate cell adhesion and 
migration. Cell adhesion was calculated by assessing the 
increase in the mean resistance at 2 h following cell seeding, 
and increased adhesion was demonstrated in the Psoriasin 
knockdown cells compared with the control cells (Fig. 3B). 
At 4‑5 h, when adhesion was complete, as determined by the 
plateauing of resistance readings, the confluent monolayer of 
cells was damaged by passing a high voltage current through it 
via an electrode. Migration was then calculated from the subse‑
quent mean resistances recorded at 0, 1, 2, 3 and 4 h (Fig. 3C). 
It was shown that the migration of HaCaTPSOkd cells increased 
significantly (P<0.01) when compared with HaCaTpEF cells.
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Figure 1. Expression of Psoriasin in wound tissues. (A) Immunochemical staining of Psoriasin in wound tissues (n=12) is shown in wound edges compared with 
staining in matched distal area. Images 4‑12 were reduced from images captured at x4 magnification. (B) Semi‑quantitative analysis of the immunochemical 
Psoriasin staining intensity at the wound edge and the distal wound. Staining intensity in 12 wound samples was analysed using ImageJ software. Three separate 
readings within the epidermal layers were normalised to the background. Means of these readings arepresented ± standard error of the mean. A 19.8% relative 
increase of Psoriasin staining in the wound edge is observed, compared with the distal wound (P=0.067). (C) Quantity of Psoriasintranscripts in acute and chronic 
wounds and normal skin was determined using quantitative polymerase chain reaction. Psoriasin transcript levels were normalised against their corresponding 
GAPDH. Due to the spread of data, the y‑axis is presented as a logarithmic scale. There is a significant difference between the acute and chronic wounds 
(P=0.0021) and between the acute wound and the normal skin (P=0.037). There is no significant difference between the chronic wound and normal skin (P=0.66).
Figure 2. Psoriasin knockdown in HaCaT cells. (A) Agarose gel electrophoresis following reverse transcription‑quantitative polymerase chain reaction demon‑
strate successful Psoriasin knockdown by the absence of a band at 246 bp. The internal control GAPDH is displayed alongside. (B) Knockdown of Psoriasin at 
the mRNA level was also confirmed using quantitative polymerase chain reaction. Displayed are Psoriasin transcripts (copies) normalised against corresponding 
GAPDH controls. (C) Western blot analysis for expression of Psoriasin protein in HaCaT cells revealed that reduced levels of Psoriasin protein expression in 
HaCaTPSOkd cells in comparison with HaCaTpEF control cells. (D) Subsequent semi‑quantitative analysis and normalisation to GAPDH indicates a marked decrease 
in Psoriasin expression following transfection with the ribozyme transgene. WT, wild type; pEF, transfected with an empty vector; PSOkd, Psoriasin knockdown.
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A ssocia t ion of  N‑WA SP,  ROCK and FA K wi th 
Psoriasin‑regulated cell adhesion and migration. To eluci‑
date the underlying mechanisms that alter the adhesion and 
migration of HaCaT cells following knockdown of Psoriasin, 
small molecule inhibitors were used to evaluate the roles of 
some associated molecules. N‑WASP inhibitor wiskostatin 
was used at a concentration of 200 nM. In the presence of the 
N‑WASP inhibitor, HaCaTPSOkd demonstrated a significant 
reduction in adhesion rate (P<0.001; Fig. 4A). The relative 
percentage of inhibition compared with the corresponding 
untreated cell line was 79% for HaCaTpEF and 77.4% for 
HaCaTPSOkd, which is significant. N‑WASP inhibition induced 
a reduction in the rate of keratinocyte migration across a 
wound similar to the effect on adhesion (Fig. 4B). The effect 
of inhibition in both cell lines was significant (P<0.001), and 
comparing the relative percentile of reduction (HaCaTpEF, 
85%; HaCaTPSOkd, 68.6%), it appears that N‑WASP inhibition 
is less effective at reducing cell migration in the Psoriasin 
knockdown cells.
ROCK inhibitor significantly increased (P<0.001) the rate 
of cell adhesion in the HaCaTpEF cell line by a factor of 163%, 
as demonstrated in Fig. 5A. However, in the HaCaTPSOkd cells 
ROCK inhibitor induced a significant reduction (P<0.01) in the 
rate of cell adhesion, with a percentile difference of 45%. The 
HaCaT cell adhesion rate in the HaCaTPSOkd group remained 
higher compared with that of the HaCaTpEF control group. The 
pattern of influence on migration was similar to that seen for 
adhesion (Fig. 5B). HaCaTpEF cells continued to demonstrate a 
significant increase (P<0.01) in cell migration in the presence 
of ROCK inhibitor, whereas the HaCaTPSOkd cells exhibited a 
Figure 3. Influence of Psoriasin knockdown on cellular functions of HaCaT 
cells. (A) Effect on cell growth was assessed using a colormetric assay 
with crystal violet staining and absorbance was measured at 540 nm. 
(B) Adhesion and (C) migration of HaCaT cells were determined using elec‑
tric cell‑substrate impedance sensingassays. Six repeats of each group were 
performed in each experiment. Six repeats were included in each adhesion 
assay while triplicates for each cell lines were included in each migration 
assay. Three independent experiments were performed. Data are presented 
as the mean ± standard error of the mean. **P<0.01 vs. the corresponding 
HaCaTpEF cells. pEF, transfected with an empty vector; PSOkd, Psoriasin 
knockdown.
Figure 4. Association of N‑WASP in the Psoriasin knockdown altered 
adhesion and migration of HaCaT cells. (A) Adhesion of HaCaT cells was 
determined using an electric cell‑substrate impedance sensing assay. A 
significant increase was observed in the rate of adhesion in HaCaTPSOkd 
compared with HaCaTpEF (P=0.002). N‑WASP inhibition significantly 
reduces the rate of adhesion in HaCaTpEF and HaCaTPSOkd cell lines. The 
relative percentage of the inhibition in the HaCaTpEF cell line is 79% and in 
HaCaTPSOkd is 77.4%. (B) Effect of N‑WASP inhibitor on migration of HaCaT 
cells. Inhibition with N‑WASP demonstrated a significant reduction in the 
rate of cell migration. The relative percentage of reduction in migration 
with N‑WASP inhibitor in HaCaTpEF is 85% and in HaCaTPSOkd is 68.6%. 
Experiments were repeated four times. The absolute resistance is presented 
as the mean ± the standard error of the mean. ***P<0.001. N‑WASP, neural 
Wiskott‑Aldrich syndrome protein; i, inhibition; pEF, transfected with an 
empty vector; PSOkd, Psoriasin knockdown.
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reduction in cell migration in the presence of ROCK inhibitor 
(P<0.01).
HaCaTpEF cell adhesion was increased with FAK inhibition, 
as illustrated in Fig. 6A. However, FAK inhibition induced 
a reduction in cell adhesion rate in HaCaTPSOkd cells. Both 
changes were significant (P<0.001) compared with untreated 
equivalents, ranging from ≤38% in the HaCaTpEF cell group 
to ≤54% in the HaCaTPSOkd group. A similar pattern to that 
of adhesion was observed in cell migration (Fig. 6B) and 
HaCaTpEF cell migration was significantly increased by FAK 
inhibition (P<0.001).
Discussion
The expression of the S100 family calcium responsive signal‑
ling protein Psoriasin was studied in normal and chronic 
wound tissue. IHC staining for Psoriasin was visualized, 
and results were in accordance with the known expression 
patterns of Psoriasin in wound tissue (39). The present study 
demonstrated a 19.8% increase in Psoriasin levels at the 
leading wound edge of the chronic wound compared with 
the distal end. This is consistent with previous reports of 
increased Psoriasin expression within wounds (39). However, 
within the chronic wound phenotype, Psoriasin mRNA levels 
are not significantly increased when compared with normal 
skin. This suggests that chronic wounds may be influenced 
by reduced Psoriasin expression; however, further study is 
required to clarify its value as a chronic wound biomarker. 
The findings of the present study correlate with the available 
data that Psoriasin expression is significantly increased in 
acute wounds (39). This suggests that Psoriasin has a notable 
influence at the leading wound edge in chronic wounds, and in 
acute wounds. Furthermore, Psoriasin may have an application 
as a biomarker for wound phenotyping and may also be used 
therapeutically to alter cell behaviour and increase wound 
healing rates. In conjunction with other cells types, the role 
of keratinocytes is critical in the healing of chronic cutaneous 
wounds. Their main function is to re‑epithelialize the wound 
surface, thereby re‑establishing epidermal cover, integrity and 
barrier function. This process encompasses a series of steps 
including proliferation, migration and differentiation (46,47). 
Figure 5. Association of ROCK in the Psoriasin knockdown altered adhesion 
and migration of HaCaT cells. (A) There is a statistically significant increase 
in the rate of adhesion in the HaCaTpEF cell population following ROCK 
inhibition, with a relative increase of 163% in comparison with the control. 
Conversely, HaCaTPSOkd demonstrate a significant inhibition of cell adhe‑
sion in the presence of ROCK inhibitors with a relative percentage of 45%. 
(B) There is a 181% increase in the rate of migration of the HaCaTpEFcells 
following ROCK inhibition and this is significant on two‑tail t‑test (P<0.001). 
Within the HaCaTPSOkd cells the reduction in the rate of cell migration is also 
significant and by a relative 43%. Experiments were repeated four times. The 
absolute resistance is presented as the mean ± the standard error of the mean. 
**P<0.01; ***P<0.001. ROCK, rho‑associated protein kinase; i, inhibition; 
pEF, transfected with an empty vector; PSOkd, Psoriasin knockdown.
Figure 6. Association of FAK in the Psoriasin knockdown altered adhesion 
and migration of HaCaT cells. (A) FAK inhibitor significantly increase the 
rate of adhesion in HaCaTpEF cells by 38% (P<0.01). Within the HaCaTPSOkd 
cells there is a significant reduction of 54% in the adhesion rate with FAK 
inhibition. (B) FAK inhibition significantly increases the rate of cell migra‑
tion in HaCaTpEF control cells by 57% (P<0.01). FAK inhibition significantly 
reduces the rate of cell migration in HaCaTPSOkd cells by a factor of 42%. 
The absolute resistance is presented as the mean ± the standard error of the 
mean. ***P<0.001; **P<0.01. FAK, focal adhesion kinase; i, inhibition; pEF, 
transfected with an empty vector; PSOkd, Psoriasin knockdown.
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To study some of these effects in vitro, the naturally immor‑
talised HaCaT cell line was used.
In order to examine the effects of Psoriasin in keratinocytes, 
an in vitro model downregulating Psoriasin in HaCaT was 
used. Psoriasin knockdown was chosen as Psoriasinis already 
expressed in normal keratinocytes. The proliferation crystal 
violet assay identified a significant increase in the growth rate 
of HaCaTPSOkd cells compared with HaCaTpEF controls. Together 
with the expression pattern seen in the IHC of Psoriasin in 
wounds, this suggests that Psoriasin may serve differential 
roles in different locations within wound tissues, such as cells 
proximal and distal to wound edges. Upregulation of Psoriasin 
production and secretion was initially noted among psoriatic 
skin lesions (16) and was subsequently attributed to inflamma‑
tion (23,24). However, further evidence of elevated Psoriasin 
expression in bladder and breast cancer was observed (17,29). 
Furthermore, an increase in Psoriasin expression levels was 
demonstrated among precancerous skin lesions and malignant 
epithelial tumours (squamous and basal cell carcinomas) (28), 
independent of differentiation and inflammation. It has 
therefore been suggested that this overexpression may be an 
important factor in tumour proliferation and progression.
Similarly, when compared with the corresponding HaCaT 
pEF6 control, in vitro ECIS migration assays show that down‑
regulation of Psoriasin in HaCaT cells results in a significant 
increase in the rate of cell migration across a wounded area. 
At present, this increased migratory effect has only been 
noted in association with Psoriasin overexpression, similar to 
cell proliferation, which has also led to attributing Psoriasin 
to cancer progression. In addition, adhesion was found to be 
significantly increased, which is in accordance with previous 
findings where loss of adhesion, attributed to cancer cell inva‑
siveness and progression, was associated with the upregulation 
of Psoriasin. The in vitro findings of the present study there‑
fore suggest that increased cellular adhesion associated with 
downregulation of Psoriasin may explain the phenomenon of 
cancer progression from reduced adhesion, as has been noted 
with Psoriasin overexpression.
The results of the present study conflict somewhat, in that 
significantly lower levels of Psoriasin are present in chronic 
wound tissue compared with acute wound tissue and ribozyme 
suppression of Psoriasin expression in HaCaT cells enhanced 
cell migration and growth, which are traits typically found in 
healing tissues. The mechanisms underlying this are currently 
unknown, however it may be hypothesized that these findings 
will likely be due to the inherent differences between in vitro 
models and complex tissue, comprising multiple cell types, 
cytokine and growth factors. It is possible that Psoriasin may 
have a prominent role in HaCaT biology, although this may 
only be obvious or significant when various other complex 
factors and interactions are also considered.
The high expression of Psoriasin in abnormal and prolif‑
erative lesions of squamous epithelia (18,26,48) suggest that 
it serves a role in the regulation of cell growth and survival. 
The contrasting evidence of increased migration and cell 
proliferation with Psoriasin knockdown may suggest that an 
alternative pathway, which is blocked by Psoriasin, stimulates 
cell growth and migration. However, the increased adhesion 
with knockdown suggests that Psoriasin downregulation is 
unlikely to be associated with cancer proliferation. Overall, 
Psoriasin function appears to be important in maintaining 
cellular homeostasis, particularly with respect to cell prolif‑
eration, migration, adhesion and differentiation.
N‑WASP is a member of the Wiskott‑Aldrich syndrome 
family of proteins, which are widely involved in signal 
transduction from receptors on the cell surface to the actin 
cytoskeleton. The actin cytoskeleton is a dynamic filament 
network that is essential for cell movement, polarisation, 
morphogenesis and cell division, which was first described as 
a 65 kDa protein from the brain that bound to SH3 domains of 
Ash/Grb2 (49). Having a sequence that was 50% homologous 
with Wiskott‑ Aldrich syndrome protein (WASP), this novel 
protein was termed N‑WASP (50,51).
N‑WASP has been implicated in various actin‑dependent 
processes, such as filopodium formation and the motility of 
Shigella (52). N‑WASP and complexes with other proteins, 
such as Arp2/3, comprise a core mechanism for the stimula‑
tion of actin polymerisation and actin assembly (53,54). A 
reduction of N‑WASP has been shown to be associated with 
a greater malignant potential in breast cancer via its role in 
cell migration and invasion, and interaction with FAK (55,56). 
In keratinocytes, knockout of N‑WASP has previously been 
shown to reduce cellular proliferation (57). However, in‑house 
studies (Jiang et al, unpublished data), have revealed increased 
keratinocyte migration in vitro with N‑WASP inhibition by 
using the inhibitor wiskostatin. Similarly, inhibiting N‑WASP 
by applying inhibitors topically and via the intraperitoneal 
route to mice enhanced wound closure rates (Jiang et al, 
unpublished data). As a result of these findings, a patent has 
been put in place to develop this product into a licensed treat‑
ment for hard‑to‑heal ulcers (Cardiff University patent, March 
2009, ID 090 4886.9) (58).
ROCK1 and 2 occur in mammals (59) and are part of a 
group of kinases belonging to the AGC family of serine‑thre‑
onine kinases. They are primarily involved in cell shape 
regulation, actin organisation on the cytoskeleton and hence 
cell migration. ROCK1 has a wide range of cellular functions 
including cellular contractility, migration, cytokinesis and 
cell‑cell adhesion, via its downstream effector function of small 
GTPase Rho, which is a major cytoskeleton regulator (60,61). 
ROCK 2 is primarily located in the brain and heart (62,63). 
These kinasesalso serve an important role in smooth muscle 
contractility, neuronal development and nerve generation (64). 
Elevated ROCK protein levels in human breast, hepatocellular, 
bowel and bladder cancers have been demonstrated to corre‑
late with increased tumour grade and poor overall survival 
rates (64,65). In keratinocytes, differentiation is prevented and 
proliferation increased by ROCK inhibition, and a two‑fold 
upregulation in Psoriasin following activation of ROCK2 has 
also been reported (66). ROCK‑signalling pathways serve 
important roles in various human diseases and have been 
considered as potential targets for the treatment of these 
diseases, including cancer, leading to increased interest in the 
pharmacological potential of ROCK inhibitors (67). In terms 
of wound healing, ROCK inhibitors have previously been 
demonstrated to enhance corneal endothelial healing (68).
FAK, also known as protein tyrosine kinase 2, is a focal 
adhesion‑associated protein kinase encoded in humans by the 
PTK2 gene. This cytoplasmic protein tyrosine kinase is found 
concentrated in the focal adhesions that form among cells 
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attaching to extracellular matrix (ECM) constituents (69). 
Most cells express FAK, and activation of the FAK tyrosine 
kinase promote cell contacts with ECM and promotes cell 
migration (69). The most well‑characterised mechanism 
promoting FAK activation is integrin receptor clustering 
upon the binding of cells to ECM proteins, which leads to 
FAK dimerisation, autophosphorylation, SRC‑family kinase 
binding and activated complex formation (69‑71).
FAK is a multifunctional regulator of cell signalling within 
a tumour microenvironment, and is overexpressed and acti‑
vated in several advanced stage‑solid cancers (72). An increase 
in FAK mRNA levels has been demonstrated in serous ovarian 
tumours, invasive breast cancers, head and neck squamous cell 
carcinoma, colorectal malignancy and various other human 
malignancies (72). At the cellular level, FAK is thought to 
be associated with various signalling pathways that promote 
cancer growth and metastasis. It increases cell motility via 
ARP2/3, affects survival via p53 and MDM2 and induces cell 
cycle progression via cyclin D1 SRC‑ERK or JUN (72). Small 
molecule FAK inhibitors have chemotherapeutic potential, as 
indicated in mouse models where FAK inhibition has been 
demonstrated to prevent tumour growth, metastasis, vascular 
permeability and angiogenesis (73‑75). Among keratinocytes 
FAK has previously been revealed to be necessary for cell 
survival in vitro due to massive apoptosis, although this is 
not true in vivo. The same study group established FAK 
expression in mouse epidermis, thinner epidermis/hair cycle 
irregularities with no effect on wound healing rates in FAK 
knockdown mice (76). To our knowledge, no reports currently 
exist studying interactions between FAK and Psoriasin.
In conclusion, Psoriasin is expressed in keratinocytes and is 
a fundamental regulator of keratinocyte migration. Significant 
increases in the rate of keratinocyte adhesion, migration 
and growth have been observed in Psoriasin‑deficient cells. 
N‑WASP, FAK, and ROCK proteins serve certain roles in the 
Psoriasin‑regulated cell adhesion and motility, implicating 
that Psoriasin may be associated with wound healing, thereby 
endorsing Psoriasin as a molecule of interest and a potential 
wound biomarkers.
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